Track the Lexeo Therapeutics, Inc. share price and the full insider trade history of the company, a listed issuer based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Market capitalisation: €404.5m. The latest transaction was reported on 18 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Townsend Richard Nolan. Every trade is accessible without an account.
72
Insider Decl.
n/a
Thresholds
€100,050
1 ops.
Buy Volume
€457,907
24 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Lexeo Therapeutics, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$20.30.
40Σ signal
Buys €100,050€457,907 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Lexeo Therapeutics, Inc. is a company focused on developing gene therapies for rare genetic diseases. It emphasizes innovation in DNA-based treatment solutions.